Skip to main content
Journal cover image

Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022.

Publication ,  Journal Article
Tenforde, MW; Patel, MM; Lewis, NM; Adams, K; Gaglani, M; Steingrub, JS; Shapiro, NI; Duggal, A; Prekker, ME; Peltan, ID; Hager, DN; Gong, MN ...
Published in: Clin Infect Dis
March 21, 2023

BACKGROUND: The COVID-19 pandemic was associated with historically low influenza circulation during the 2020-2021 season, followed by an increase in influenza circulation during the 2021-2022 US season. The 2a.2 subgroup of the influenza A(H3N2) 3C.2a1b subclade that predominated was antigenically different from the vaccine strain. METHODS: To understand the effectiveness of the 2021-2022 vaccine against hospitalized influenza illness, a multistate sentinel surveillance network enrolled adults aged ≥18 years hospitalized with acute respiratory illness and tested for influenza by a molecular assay. Using the test-negative design, vaccine effectiveness (VE) was measured by comparing the odds of current-season influenza vaccination in influenza-positive case-patients and influenza-negative, SARS-CoV-2-negative controls, adjusting for confounders. A separate analysis was performed to illustrate bias introduced by including SARS-CoV-2-positive controls. RESULTS: A total of 2334 patients, including 295 influenza cases (47% vaccinated), 1175 influenza- and SARS-CoV-2-negative controls (53% vaccinated), and 864 influenza-negative and SARS-CoV-2-positive controls (49% vaccinated), were analyzed. Influenza VE was 26% (95% CI: -14% to 52%) among adults aged 18-64 years, -3% (-54% to 31%) among adults aged ≥65 years, and 50% (15-71%) among adults aged 18-64 years without immunocompromising conditions. Estimated VE decreased with inclusion of SARS-CoV-2-positive controls. CONCLUSIONS: During a season where influenza A(H3N2) was antigenically different from the vaccine virus, vaccination was associated with a reduced risk of influenza hospitalization in younger immunocompetent adults. However, vaccination did not provide protection in adults ≥65 years of age. Improvements in vaccines, antivirals, and prevention strategies are warranted.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

March 21, 2023

Volume

76

Issue

6

Start / End Page

1030 / 1037

Location

United States

Related Subject Headings

  • Young Adult
  • Vaccine Efficacy
  • United States
  • Seasons
  • SARS-CoV-2
  • Middle Aged
  • Microbiology
  • Male
  • Influenza, Human
  • Influenza Vaccines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tenforde, M. W., Patel, M. M., Lewis, N. M., Adams, K., Gaglani, M., Steingrub, J. S., … Influenza and Other Viruses in the Acutely Ill (IVY) Network. (2023). Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022. Clin Infect Dis, 76(6), 1030–1037. https://doi.org/10.1093/cid/ciac869
Tenforde, Mark W., Manish M. Patel, Nathaniel M. Lewis, Katherine Adams, Manjusha Gaglani, Jay S. Steingrub, Nathan I. Shapiro, et al. “Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022.Clin Infect Dis 76, no. 6 (March 21, 2023): 1030–37. https://doi.org/10.1093/cid/ciac869.
Tenforde MW, Patel MM, Lewis NM, Adams K, Gaglani M, Steingrub JS, et al. Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022. Clin Infect Dis. 2023 Mar 21;76(6):1030–7.
Tenforde, Mark W., et al. “Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022.Clin Infect Dis, vol. 76, no. 6, Mar. 2023, pp. 1030–37. Pubmed, doi:10.1093/cid/ciac869.
Tenforde MW, Patel MM, Lewis NM, Adams K, Gaglani M, Steingrub JS, Shapiro NI, Duggal A, Prekker ME, Peltan ID, Hager DN, Gong MN, Exline MC, Ginde AA, Mohr NM, Mallow C, Martin ET, Talbot HK, Gibbs KW, Kwon JH, Chappell JD, Halasa N, Lauring AS, Lindsell CJ, Swan SA, Hart KW, Womack KN, Baughman A, Grijalva CG, Self WH, Influenza and Other Viruses in the Acutely Ill (IVY) Network. Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022. Clin Infect Dis. 2023 Mar 21;76(6):1030–1037.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

March 21, 2023

Volume

76

Issue

6

Start / End Page

1030 / 1037

Location

United States

Related Subject Headings

  • Young Adult
  • Vaccine Efficacy
  • United States
  • Seasons
  • SARS-CoV-2
  • Middle Aged
  • Microbiology
  • Male
  • Influenza, Human
  • Influenza Vaccines